John J. Strouse, MD, PhD, and Julie Kanter, MD, join guest host Ify Osunkwo, MD, of Levine Cancer Institute/Atrium Health in Charlotte, N.C., to discuss current therapies for sickle cell disease, as well as new treatments and cures under development.
Ilana Yurkiewicz, MD, tackles informed consent and the capacity to choose in cancer care with a focus on the research setting. Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford University and is a columnist for Hematology News. More from Dr. Yurkiewicz here.
BY EMILY BRYER, DO
Resident in the department of internal medicine, University of Pennsylvania Health System.
Sickle cell disease is a multi-organ system vascular disease that affects both children and adults.
Pathophysiology in sickle cell disease includes increased expression of adhesion molecules resulting in vessel obstruction, activation of coagulation cascade and inflammatory cytokines, and a relative deficiency of nitric oxide that limits blood vessel dilatation.
Universal newborn screening has translated into earlier diagnoses of sickle cell disease with improved outcomes.
Therapeutics for sickle cell disease are limited, with only two FDA approved medications:
Comprehensive Center (multidisciplinary team) remains the gold standard for sickle cell disease treatment, however many patients are limited by geographic location and/or by medical insurance.
EMBRACE (Education and Mentoring to Bring Access to CarE) Network:
New and emerging therapies for sickle cell disease:
Are you the creator of this podcast?
and pick the featured episodes for your show.
Connect with listeners
Podcasters use the RadioPublic listener relationship platform to build lasting connections with fansYes, let's begin connecting
Find new listeners
Understand your audience
Engage your fanbase